1. Home
  2. RNTX vs FSI Comparison

RNTX vs FSI Comparison

Compare RNTX & FSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RNTX

Rein Therapeutics Inc.

SELL

Current Price

$0.70

Market Cap

65.3M

Sector

Health Care

ML Signal

SELL

Logo Flexible Solutions International Inc. (CDA)

FSI

Flexible Solutions International Inc. (CDA)

N/A

Current Price

$6.07

Market Cap

63.7M

ML Signal

N/A

Company Overview

Basic Information
Metric
RNTX
FSI
Founded
2001
1991
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Recreational Games/Products/Toys
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
65.3M
63.7M
IPO Year
2017
2000

Fundamental Metrics

Financial Performance
Metric
RNTX
FSI
Price
$0.70
$6.07
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $6.00
N/A
AVG Volume (30 Days)
★ 325.7K
9.9K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
★ 1.65%
EPS Growth
★ 44.16
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $15,494,325.00
Revenue This Year
N/A
$24.09
Revenue Next Year
N/A
$60.56
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.69
$4.85
52 Week High
$2.18
$9.89

Technical Indicators

Market Signals
Indicator
RNTX
FSI
Relative Strength Index (RSI) 38.79 54.16
Support Level N/A $5.95
Resistance Level $0.87 $6.11
Average True Range (ATR) 0.06 0.18
MACD -0.01 -0.01
Stochastic Oscillator 11.04 35.00

Price Performance

Historical Comparison
RNTX
FSI

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

About FSI Flexible Solutions International Inc. (CDA)

Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The company also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.

Share on Social Networks: